Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy

Eye

Volumn 24, Issue 4, 2010, Pages 717-719

  Falavarjani, K Ghasemi ^a   Modarres, M ^a   Nazari, H ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Diabetic retinopathy; Neovascular glaucoma; Silicone oil; Vitrectomy

Indexed keywords

BEVACIZUMAB; BRIMONIDINE; DORZOLAMIDE; SILICONE OIL; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS NEOVASCULARIZATION; MALE; NEOVASCULAR GLAUCOMA; PSEUDOPHAKIA; REMISSION; THERAPY EFFECT; VISUAL ACUITY; VITRECTOMY;

EID: 77951099258     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.94     Document Type: Article

References (14)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
2. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous level of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26: 871-876.
3. Sivak-callcott JA, O'Day DM, Gass DM, Tsai JC. Evidencebased recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108: 1767-1776.
4. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155-158.
5. Cheng JYC, Wong DWK, Ang CL. Intraocular Avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma. Ann Acad Med Singapore 2008; 37: 72-74.
6. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz- Schmidt KU, The Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-160.
7. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115(9): 1571-1580.
8. Gallemore RP, McCuen BW. Silicone oil in vitreoretinal surgery. In: Ryan SJ (ed.) Retina, 4th edition. St Louis: Mosby, 2006; pp 2211-2234.
9. Avery RL. Intravitreal bevacizumab in the surgical treatment of proliferative diabetic retinopathy. Retina today, March/April 2008; 50-53.
10. Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006; 26(8): 877-881.
11. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo Jr LA, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006; 47: 4569-4578.
12. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008; 28: 212-219.
13. Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5mg vs 1.25mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009; 29(3): 319-324.
14. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-261.